Key questions employers should ask their PBM about GLP-1s As oral GLP-1s join formularies, employers should be discussing these key questions with their PBM, looking beyond coverage decisions to what will truly drive outcomes: Patient selection: How do you identify clinically appropriate candidates, not just anyone requesting treatment
Side-by-side dosage chart comparison This is what most people are actually looking for
A: It may slightly impact insulin sensitivity or glucose metabolism due to IGF-1 increases
Heres how dosing compares: Semaglutide Wegovy (injection): Taken once weekly, starting at 0.25 mg once and gradually increased as needed but not earlier than every 4 weeks, up to 7.2 mg, as needed
Chronic dry mouth, also known as xerostomia, can make it harder to eat, speak, and even sleep, while increasing the risk of tooth decay and gum disease